Company: CERO
Filing Date: 2025-12-05
Form Type: S-1
Source: 0001213900-25-118817
Chunk: 406

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-12-05
Form: S-1
Chunk 406
---
apeutics, Inc. (“Predecessor”), which was incorporated in Delaware on September 23, 2016, and based in South San Francisco, California, entered into a Business Combination Agreement and Plan of Reorganization (the “BCA”) with PBCE Merger Sub, Inc., a wholly-owned subsidiary of PBAX, and PBAX, with the surviving operating entity being named CERo Therapeutics Holdings, Inc. (“Successor” or the “Company”), and such transaction, the “Business Combination” or “Merger”.

The Company is focused on
genetically engineering human immune cells to fight cancer. The Predecessor focused on developing the CERo therapeutic platform and had
not yet begun clinical development or product commercialization. The Company’s efforts will focus on continued product development,
including clinical development, to support regulatory approval to commercialize and subsequent product commercialization.

The BCA was amended on February
5, 2024 and again on February 13, 2024. The Merger closed on February 14, 2024 (the “Closing”), at which time the following
occurred:

| 1. | The outstanding shares of Predecessor’s Preferred Stock were converted                                      
 into 2,208 shares of Common Stock, par value $0.0001 per share (the “Common Stock”), valued at $21,635,926. |

| 2. | The outstanding shares of Predecessor’s common stock were converted 
 into 292 shares of Common Stock, valued at $2,864,074.              |

| 3. | Each holder of Predecessor’s common stock received a pro                                                                                     
 rata portion of up to 600 earnout shares of restricted Common Stock (the “BCA Earnout Shares”), valued at $5,880,000, 500                    
 shares of which are subject to vesting upon the achievement of certain stock price-based earnout targets and 100 shares of which are subject 
 to vesting upon a change of control, respectively.                                                                                           |

| 4. | Certain holders of Predecessor’s common stock received a pro rata portion                                                  
 of 438 earnout shares of Common Stock (the “Reallocation Shares”), valued at $4.29 million, which became fully vested upon 
 the Closing.                                                                                                               |

| 5. | Certain holders of Predecessor’s common stock and convertible bridge                                                                 
 notes received a pro rata portion of 500 earnout shares (the “IND Earn